Ruben Garcia Buys 140,000 Shares of FibroBiologics (NASDAQ:FBLG) Stock

FibroBiologics Inc. (NASDAQ:FBLG) General Counsel Ruben Garcia purchased 140,000 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The stock was acquired at an average price of $0.34 per share, for a total transaction of $47,600.00. Following the acquisition, the general counsel owned 140,000 shares in the company, valued at $47,600. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

FibroBiologics Trading Up 13.0%

Shares of NASDAQ FBLG opened at $0.39 on Friday. The company has a 50 day simple moving average of $0.36 and a two-hundred day simple moving average of $0.55. The stock has a market cap of $20.93 million, a price-to-earnings ratio of -0.82 and a beta of -0.58. FibroBiologics Inc. has a 12 month low of $0.24 and a 12 month high of $2.51.

FibroBiologics (NASDAQ:FBLG) last released its quarterly earnings data on Friday, October 31st. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.03). Analysts forecast that FibroBiologics Inc. will post -0.53 EPS for the current year.

Institutional Investors Weigh In On FibroBiologics

Institutional investors have recently modified their holdings of the business. AQR Capital Management LLC purchased a new position in shares of FibroBiologics in the 1st quarter valued at about $29,000. XTX Topco Ltd grew its holdings in FibroBiologics by 160.0% in the second quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock valued at $29,000 after purchasing an additional 28,276 shares during the period. Ethos Financial Group LLC increased its position in shares of FibroBiologics by 100.0% in the second quarter. Ethos Financial Group LLC now owns 48,848 shares of the company’s stock valued at $30,000 after buying an additional 24,424 shares in the last quarter. Nuveen LLC acquired a new position in shares of FibroBiologics during the 1st quarter worth approximately $31,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of FibroBiologics during the 2nd quarter valued at approximately $37,000.

Analyst Upgrades and Downgrades

FBLG has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of FibroBiologics in a research note on Wednesday, October 8th. D. Boral Capital reaffirmed a “buy” rating and set a $15.00 target price on shares of FibroBiologics in a report on Thursday, November 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of FibroBiologics in a report on Friday, September 12th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $12.50.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.